Literature DB >> 2540431

Regulation of epidermal growth factor receptor gene expression.

L G Hudson1, J B Santon, G N Gill.   

Abstract

Synthesis and metabolism of the epidermal growth factor (EGF) receptor are extensively regulated to modulate cellular responses to ligand. To study regulation of EGF receptor gene expression, the 5' region of the gene was isolated from a human placental genomic library. A 5' proximal 1.1-kilobase fragment (-1100 to -19 relative to the ATG translation start site) and subfragments of this were subcloned in both forward and reverse orientations into the luciferase expression vector pSVOAL delta 5' and transfected into human cell lines. Luciferase activity was stimulated by treatment of transfected HeLa cells with EGF, 12-O-tetradecanoylphorbol 13-acetate (TPA), (Bu)2 cAMP, retinoic acid, and dexamethasone. Deletion analysis indicated full retention of activity after removal of the -1100 to -485 region (-485 to -19 fragment), but a 5-fold reduction in activity on removal of the -485 to -153 region (-153 to -19 fragment). Despite a reduction in basal activity, the proximal 134-basepair fragment retained responses to all inducers. Additivity was observed in response to maximal concentrations of TPA plus retinoic acid and of TPA plus (Bu)2 cAMP; the response to a combination of four inducers exceeded that to the RSV-LTR strong promoter. Differences in stimulated responses were observed in various recipients, with hepatoma HepG2 cells lacking responses to (Bu)2 cAMP and glioblastoma T98G cells lacking responses to EGF and TPA. These results indicate that a 134-basepair DNA fragment closely adjacent to the translation start site contains elements responsible for directing basal and stimulated expression of the EGF receptor gene.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2540431     DOI: 10.1210/mend-3-2-400

Source DB:  PubMed          Journal:  Mol Endocrinol        ISSN: 0888-8809


  9 in total

Review 1.  Transcriptional regulation of type I receptor tyrosine kinases in the mammary gland.

Authors:  N P Bates; H C Hurst
Journal:  J Mammary Gland Biol Neoplasia       Date:  1997-04       Impact factor: 2.673

2.  Identification and characterization of a regulated promoter element in the epidermal growth factor receptor gene.

Authors:  L G Hudson; K L Thompson; J Xu; G N Gill
Journal:  Proc Natl Acad Sci U S A       Date:  1990-10       Impact factor: 11.205

3.  Characterization of a DNA-damage-recognition protein from F9 teratocarcinoma cells, which is inducible by retinoic acid and cyclic AMP.

Authors:  C C Chao; N K Sun; S Lin-Chao
Journal:  Biochem J       Date:  1993-02-15       Impact factor: 3.857

Review 4.  Protein kinase C isozymes and substrates in mammary carcinogenesis.

Authors:  S C Kiley; J Welsh; C J Narvaez; S Jaken
Journal:  J Mammary Gland Biol Neoplasia       Date:  1996-04       Impact factor: 2.673

5.  Induction, not associated with host-cell re-activation of damaged plasmid DNA, of damaged-DNA-recognition proteins by retinoic acid and dibutyryl cyclic AMP in mammalian cells.

Authors:  N K Sun; S L Huang; S Lin-Chao; C C Chao
Journal:  Biochem J       Date:  1996-01-15       Impact factor: 3.857

Review 6.  EGF receptor expression, regulation, and function in breast cancer.

Authors:  S A Chrysogelos; R B Dickson
Journal:  Breast Cancer Res Treat       Date:  1994-01       Impact factor: 4.872

7.  The promyelocytic leukemia protein interacts with Sp1 and inhibits its transactivation of the epidermal growth factor receptor promoter.

Authors:  S Vallian; K V Chin; K S Chang
Journal:  Mol Cell Biol       Date:  1998-12       Impact factor: 4.272

8.  Bradykinin-induced growth inhibition of normal rat kidney (NRK) cells is paralleled by a decrease in epidermal-growth-factor receptor expression.

Authors:  E J Van Zoelen; P H Peters; G B Afink; S Van Genesen; D G De Roos; W Van Rotterdam; A P Theuvenet
Journal:  Biochem J       Date:  1994-03-01       Impact factor: 3.857

9.  Mechanisms of EGF receptor regulation in breast cancer cells.

Authors:  S A Chrysogelos; R I Yarden; A H Lauber; J M Murphy
Journal:  Breast Cancer Res Treat       Date:  1994       Impact factor: 4.872

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.